Advertisement
Screener

ACTINIUM PHARMACEUTICALS, INC. (ATNM) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

ACTINIUM PHARMACEUTICALS, INC. Research and Development Expense

ACTINIUM PHARMACEUTICALS, INC. (ATNM) reported Research and Development Expense of $5.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-07

  • ACTINIUM PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-06-30 was $5.38M, a 10.21% increase year-over-year.
  • ACTINIUM PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-03-31 was $4.20M, a 45.44% decline year-over-year.
  • ACTINIUM PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-12-31 was $4.30M, a 10.68% decline year-over-year.
  • ACTINIUM PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-09-30 was $4.25M, a 56.54% decline year-over-year.
  • ACTINIUM PHARMACEUTICALS, INC. research and development expense for fiscal 2025 was $21.12M, a 29.69% decline from fiscal 2024.
  • ACTINIUM PHARMACEUTICALS, INC. research and development expense for fiscal 2024 was $30.05M, a 22.30% decline from fiscal 2023.
  • ACTINIUM PHARMACEUTICALS, INC. research and development expense for fiscal 2023 was $38.67M, a 67.15% increase from fiscal 2022.
  • ACTINIUM PHARMACEUTICALS, INC. research and development expense for fiscal 2022 was $23.14M, a 28.31% increase from fiscal 2021.
Period endResearch and Development Expense 3 monthResearch and Development Expense 3 month as first filedResearch and Development Expense 6 monthResearch and Development Expense 6 month as first filedResearch and Development Expense 9 monthResearch and Development Expense 9 month as first filedResearch and Development Expense 12 monthResearch and Development Expense 12 month as first filedResearch and Development Expense 151 monthResearch and Development Expense 154 monthResearch and Development Expense 157 monthResearch and Development Expense 160 monthResearch and Development Expense 163 monthResearch and Development Expense 166 month
2026-06-30$5.38M
10-Q · filed 2026-08-07
$9.58M
10-Q · filed 2026-08-07
$13.88M
derived: sum of 3 quarters · filed 2026-08-07
$18.12M
derived: sum of 4 quarters · filed 2026-08-07
2026-03-31$4.20M
10-Q · filed 2026-05-08
$8.50M
derived: sum of 2 quarters · filed 2026-05-08
$12.75M
derived: sum of 3 quarters · filed 2026-05-08
$17.63M
derived: sum of 4 quarters · filed 2026-08-07
2025-12-31$4.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$8.54M
derived: sum of 2 quarters · filed 2026-03-30
$13.42M
derived: sum of 3 quarters · filed 2026-08-07
$21.12M
10-K · filed 2026-03-30
2025-09-30$4.25M
10-Q · filed 2025-11-14
$9.13M
derived: sum of 2 quarters · filed 2026-08-07
$16.83M
10-Q · filed 2025-11-14
$21.64M
derived: sum of 4 quarters · filed 2026-08-07
2025-06-30$4.88M
10-Q · filed 2026-08-07
$12.58M
10-Q · filed 2026-08-07
$17.39M
derived: sum of 3 quarters · filed 2026-08-07
$27.16M
derived: sum of 4 quarters · filed 2026-08-07
2025-03-31$7.70M
10-Q · filed 2026-05-08
$12.51M
derived: sum of 2 quarters · filed 2026-05-08
$22.29M
derived: sum of 3 quarters · filed 2026-05-08
$31.11M
derived: sum of 4 quarters · filed 2026-05-08
2024-12-31$4.81M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$14.59M
derived: sum of 2 quarters · filed 2026-03-30
$23.41M
derived: sum of 3 quarters · filed 2026-03-30
$30.05M
10-K · filed 2026-03-30
2024-09-30$9.77M
10-Q · filed 2025-11-14
$18.60M
derived: sum of 2 quarters · filed 2025-11-14
$25.23M
10-Q · filed 2025-11-14
$33.35M
derived: sum of 4 quarters · filed 2025-11-14
2024-06-30$8.82M
10-Q · filed 2025-08-08
$15.46M
10-Q · filed 2025-08-08
$23.58M
derived: sum of 3 quarters · filed 2025-08-08
$35.20M
derived: sum of 4 quarters · filed 2025-08-08
2024-03-31$6.63M
10-Q · filed 2025-05-09
$14.75M
derived: sum of 2 quarters · filed 2025-05-09
$26.38M
derived: sum of 3 quarters · filed 2025-05-09
$37.46M
derived: sum of 4 quarters · filed 2025-05-09
2023-12-31$8.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$19.74M
derived: sum of 2 quarters · filed 2025-03-31
$30.82M
derived: sum of 3 quarters · filed 2025-03-31
$38.67M
10-K · filed 2025-03-31
2023-09-30$11.62M
10-Q · filed 2024-11-14
$22.70M
derived: sum of 2 quarters · filed 2024-11-14
$30.55M
10-Q · filed 2024-11-14
$37.88M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$11.08M
10-Q · filed 2024-08-05
$18.93M
10-Q · filed 2024-08-05
$26.26M
derived: sum of 3 quarters · filed 2024-08-05
$33.03M
derived: sum of 4 quarters · filed 2024-08-05
2023-03-31$7.85M
10-Q · filed 2024-04-26
$15.18M
derived: sum of 2 quarters · filed 2024-04-26
$21.95M
derived: sum of 3 quarters · filed 2024-04-26
$26.61M
derived: sum of 4 quarters · filed 2024-04-26
2022-12-31$7.33M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29
$14.10M
derived: sum of 2 quarters · filed 2024-03-29
$18.77M
derived: sum of 3 quarters · filed 2024-03-29
$23.14M
10-K · filed 2024-03-29
2022-09-30$6.77M
10-Q · filed 2023-11-02
$11.43M
derived: sum of 2 quarters · filed 2023-11-02
$15.80M
10-Q · filed 2023-11-02
$21.22M
derived: sum of 4 quarters · filed 2023-11-02
2022-06-30$4.66M
10-Q · filed 2023-08-14
$9.03M
10-Q · filed 2023-08-14
$14.45M
derived: sum of 3 quarters · filed 2023-08-14
$19.16M
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31$4.37M
10-Q · filed 2023-05-15
$9.79M
derived: sum of 2 quarters · filed 2023-05-15
$14.49M
derived: sum of 3 quarters · filed 2023-05-15
$18.12M
derived: sum of 4 quarters · filed 2023-05-15
2021-12-31$5.42M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31
$10.12M
derived: sum of 2 quarters · filed 2023-03-31
$13.76M
derived: sum of 3 quarters · filed 2023-03-31
$18.03M
10-K · filed 2023-03-31
2021-09-30$4.71M
10-Q · filed 2022-11-14
$8.34M
derived: sum of 2 quarters · filed 2022-11-14
$12.62M
10-Q · filed 2022-11-14
$17.25M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30$3.63M
10-Q · filed 2022-08-12
$7.91M
10-Q · filed 2022-08-12
$12.55M
derived: sum of 3 quarters · filed 2022-08-12
$16.33M
derived: sum of 4 quarters · filed 2022-08-12
2021-03-31$4.28M
10-Q · filed 2022-05-13
$8.91M
derived: sum of 2 quarters · filed 2022-05-13
$12.70M
derived: sum of 3 quarters · filed 2022-05-13
$16.21M
derived: sum of 4 quarters · filed 2022-05-13
2020-12-31$4.64M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25
$8.43M
derived: sum of 2 quarters · filed 2022-03-25
$11.94M
derived: sum of 3 quarters · filed 2022-03-25
$16.09M
10-K · filed 2022-03-25
2020-09-30$3.79M
10-Q · filed 2021-11-12
$7.30M
derived: sum of 2 quarters · filed 2021-11-12
$11.45M
10-Q · filed 2021-11-12
$14.82M
derived: sum of 4 quarters · filed 2021-11-12
2020-06-30$3.51M
10-Q · filed 2021-07-30
$7.66M
10-Q · filed 2021-07-30
$11.03M
derived: sum of 3 quarters · filed 2021-07-30
$15.86M
derived: sum of 4 quarters · filed 2021-07-30
2020-03-31$4.15M
10-Q · filed 2021-05-14
$7.53M
derived: sum of 2 quarters · filed 2021-05-14
$12.36M
derived: sum of 3 quarters · filed 2021-05-14
$16.36M
derived: sum of 4 quarters · filed 2021-05-14
2019-12-31$3.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31
$8.20M
derived: sum of 2 quarters · filed 2021-03-31
$12.21M
derived: sum of 3 quarters · filed 2021-03-31
$16.55M
10-K · filed 2021-03-31
$16.55M
10-K · filed 2020-05-08
2019-09-30$4.83M
10-Q · filed 2020-10-23
$4.83M
10-Q · filed 2019-11-12
$8.84M
derived: sum of 2 quarters · filed 2020-10-23
$13.18M
10-Q · filed 2020-10-23
$13.18M
10-Q · filed 2019-11-12
$18.25M
derived: sum of 4 quarters · filed 2020-10-23
2019-06-30$4.01M
10-Q · filed 2020-08-14
$4.01M
10-Q · filed 2019-08-09
$8.35M
10-Q · filed 2020-08-14
$8.35M
10-Q · filed 2019-08-09
$13.42M
derived: sum of 3 quarters · filed 2020-08-14
$17.64M
derived: sum of 4 quarters · filed 2020-08-14
2019-03-31$4.34M
10-Q · filed 2020-06-29
$4.34M
10-Q · filed 2019-05-10
$9.41M
derived: sum of 2 quarters · filed 2020-06-29
$13.63M
derived: sum of 3 quarters · filed 2020-06-29
$16.96M
derived: sum of 4 quarters · filed 2020-06-29
2018-12-31$5.07M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-08
$9.30M
derived: sum of 2 quarters · filed 2020-05-08
$12.63M
derived: sum of 3 quarters · filed 2020-05-08
$17.09M
10-K · filed 2020-05-08
2018-09-30$4.23M
10-Q · filed 2019-11-12
$4.22M
10-Q · filed 2018-11-09
$7.56M
derived: sum of 2 quarters · filed 2019-11-12
$12.02M
10-Q · filed 2019-11-12
$12.01M
10-Q · filed 2018-11-09
$15.69M
derived: sum of 4 quarters · filed 2019-11-12
2018-06-30$3.33M
10-Q · filed 2019-08-09
$3.33M
10-Q · filed 2018-08-09
$7.80M
10-Q · filed 2019-08-09
$7.79M
10-Q · filed 2018-08-09
$11.47M
derived: sum of 3 quarters · filed 2019-08-09
$16.49M
derived: sum of 4 quarters · filed 2019-08-09
2018-03-31$4.47M
10-Q · filed 2019-05-10
$4.46M
10-Q · filed 2018-05-10
$8.14M
derived: sum of 2 quarters · filed 2019-05-10
$13.16M
derived: sum of 3 quarters · filed 2019-05-10
$17.61M
derived: sum of 4 quarters · filed 2019-05-10
2017-12-31$3.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15
$8.70M
derived: sum of 2 quarters · filed 2019-03-15
$13.15M
derived: sum of 3 quarters · filed 2019-03-15
$17.72M
10-K · filed 2019-03-15
$17.70M
10-K · filed 2018-03-16
2017-09-30$5.03M
10-Q · filed 2018-11-09
$4.96M
10-Q · filed 2017-11-03
$9.47M
derived: sum of 2 quarters · filed 2018-11-09
$14.05M
10-Q · filed 2018-11-09
$13.84M
10-Q · filed 2017-11-03
$18.28M
derived: sum of 4 quarters · filed 2019-03-15
2017-06-30$4.45M
10-Q · filed 2018-08-09
$4.38M
10-Q · filed 2017-08-04
$9.02M
10-Q · filed 2018-08-09
$8.88M
10-Q · filed 2017-08-04
$13.25M
derived: sum of 3 quarters · filed 2019-03-15
$18.94M
derived: sum of 4 quarters · filed 2019-03-15
2017-03-31$4.57M
10-Q · filed 2018-05-10
$4.50M
10-Q · filed 2017-05-15
$8.80M
derived: sum of 2 quarters · filed 2019-03-15
$14.49M
derived: sum of 3 quarters · filed 2019-03-15
$18.64M
derived: sum of 4 quarters · filed 2019-03-15
2016-12-31$4.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15
$9.91M
derived: sum of 2 quarters · filed 2019-03-15
$14.06M
derived: sum of 3 quarters · filed 2019-03-15
$17.83M
10-K · filed 2019-03-15
$17.50M
10-K · filed 2017-03-16
2016-09-30$5.69M
10-Q · filed 2017-11-03
$9.83M
derived: sum of 2 quarters · filed 2017-11-03
$13.60M
10-Q · filed 2017-11-03
$16.39M
derived: sum of 4 quarters · filed 2018-03-16
2016-06-30$4.15M
10-Q · filed 2017-08-04
$7.91M
10-Q · filed 2017-08-04
$10.70M
derived: sum of 3 quarters · filed 2018-03-16
$13.53M
derived: sum of 4 quarters · filed 2018-03-16
2016-03-31$3.77M
10-Q · filed 2017-05-15
$6.55M
derived: sum of 2 quarters · filed 2018-03-16
$9.38M
derived: sum of 3 quarters · filed 2018-03-16
$13.22M
derived: sum of 4 quarters · filed 2018-03-16
2015-12-31$2.79M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16
$5.62M
derived: sum of 2 quarters · filed 2018-03-16
$9.45M
derived: sum of 3 quarters · filed 2018-03-16
$13.50M
10-K · filed 2018-03-16
$13.31M
10-K · filed 2016-03-11
2015-09-30$2.83M
10-Q · filed 2016-10-28
$6.67M
derived: sum of 2 quarters · filed 2016-10-28
$10.71M
10-Q · filed 2016-10-28
$15.12M
derived: sum of 4 quarters · filed 2017-03-16
2015-06-30$3.84M
10-Q · filed 2016-07-29
$7.89M
10-Q · filed 2016-07-29
$12.29M
derived: sum of 3 quarters · filed 2017-03-16
$16.43M
derived: sum of 4 quarters · filed 2017-03-16
2015-03-31$4.05M
10-Q · filed 2016-05-10
$8.45M
derived: sum of 2 quarters · filed 2017-03-16
$12.60M
derived: sum of 3 quarters · filed 2017-03-16
$14.73M
derived: sum of 4 quarters · filed 2017-03-16
2014-12-31$4.41M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16
$8.55M
derived: sum of 2 quarters · filed 2017-03-16
$10.68M
derived: sum of 3 quarters · filed 2017-03-16
$12.27M
10-K · filed 2017-03-16
2014-09-30$4.14M
10-Q · filed 2015-10-30
$3.77M
10-Q · filed 2014-10-31
$6.27M
derived: sum of 2 quarters · filed 2015-10-30
$7.86M
10-Q · filed 2015-10-30
$8.24M
10-Q · filed 2014-10-31
$8.60M
derived: sum of 4 quarters · filed 2016-03-11
2014-06-30$2.13M
10-Q · filed 2015-08-07
$2.00M
10-Q · filed 2014-08-12
$3.72M
10-Q · filed 2015-08-07
$4.46M
10-Q · filed 2014-08-12
$4.46M
derived: sum of 3 quarters · filed 2016-03-11
$5.23M
derived: sum of 4 quarters · filed 2016-03-11
2014-03-31$1.59M
10-Q · filed 2015-05-08
$2.46M
10-Q · filed 2014-05-12
$2.33M
derived: sum of 2 quarters · filed 2016-03-11
$3.10M
derived: sum of 3 quarters · filed 2016-03-11
$3.61M
derived: sum of 4 quarters · filed 2016-03-11
$31.55M
10-Q · filed 2014-05-12
2013-12-31$736.13K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11
$1.51M
derived: sum of 2 quarters · filed 2016-03-11
$2.02M
derived: sum of 3 quarters · filed 2016-03-11
$3.11M
10-K · filed 2016-03-11
$2.67M
10-K · filed 2014-02-28
$29.09M
10-K · filed 2014-02-28
2013-09-30$778.23K
10-Q · filed 2014-10-31
$1.29M
derived: sum of 2 quarters · filed 2014-10-31
$2.37M
10-Q · filed 2014-10-31
$3.09M
derived: sum of 4 quarters · filed 2014-10-31
$28.79M
10-Q · filed 2013-11-14
2013-06-30$509.26K
10-Q · filed 2014-08-12
$1.59M
10-Q · filed 2014-08-12
$2.31M
derived: sum of 3 quarters · filed 2014-08-12
$3.99M
derived: sum of 4 quarters · filed 2014-08-12
$28.02M
10-Q · filed 2013-08-13
2013-03-31$1.09M
10-Q · filed 2014-05-12
$1.80M
derived: sum of 2 quarters · filed 2014-05-12
$3.48M
derived: sum of 3 quarters · filed 2014-05-12
$4.08M
derived: sum of 4 quarters · filed 2014-05-12
$27.51M
10-Q · filed 2013-05-15
2012-12-31$717.03K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28
$2.39M
derived: sum of 2 quarters · filed 2014-02-28
$3.00M
derived: sum of 3 quarters · filed 2014-02-28
$3.44M
10-K · filed 2014-02-28
$26.42M
10-K · filed 2013-03-29
2012-09-30$1.68M
10-Q · filed 2013-11-14
$2.28M
derived: sum of 2 quarters · filed 2013-11-14
$2.72M
10-Q · filed 2013-11-14
2012-06-30$601.27K
10-Q · filed 2013-08-13
$1.05M
10-Q · filed 2013-08-13
2012-03-31$444.89K
10-Q · filed 2013-05-15
2011-12-31$323.79K
10-K · filed 2013-03-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
FILANA THERAPEUTICS, INC. (FLNA)United States$0.038B-1.05
PMGC Holdings Inc. (ELAB)United States$0.037B
Celularity Inc (CELU)United States$0.038B-0.34
CervoMed Inc. (CRVO)United States$0.038B-1.39
BriaCell Therapeutics Corp. (BCTX)$0.037B
Edesa Biotech, Inc. (EDSA)Canada$0.039B
Seres Therapeutics, Inc. (MCRB)United States$0.036B-3.45
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98
Incannex Healthcare Inc. (IXHL)$0.040B-22.32